Genomic Medicine Sweden
| Reference number | |
| Coordinator | Karolinska Institutet - Inst. för molekylärmedicin och kirurgi |
| Funding from Vinnova | SEK 4 997 079 |
| Project duration | June 2018 - December 2018 |
| Status | Completed |
Important results from the project
Genomic Medicine Sweden (GMS) aims to strengthen precision medicine across the country. This will be accomplished through the implementation of large-scale sequencing techniques in Swedish healthcare, resulting in improved healthcare, strengthened Swedish research in the area, and provide a foundation for innovation and collaboration with industry. With a patient-centered view, initial efforts will focus on rare inherited diseases, cancer, pharmacogenomics and infectious diseases, and be extended to other complex diseases (e.g. noncommunicable diseases).
Expected long term effects
GMS has established an organizational model at the national and regional level, which is currently being implemented. The startup seed grant was focused on the disease groups for cancer (hematology and solid tumors), where a common national strategy was developed to implement the new sequencing technologies and the scope of national pilot projects was defined. Efforts on developing a national informatics platform has begun based on the inputs from the diagnostic platform special needs and ethical and legal aspects of operable frameworks.
Approach and implementation
The aim of the project was to develop an organizational foundation for GMS to enter the next step of implementing precision medicine into Swedish healthcare. This has been achieved and is now being implemented. Specific goals and results: 1) Validate and approve an organizational model and activity plan on a national level, 2) Validate and approve GMS plans within existing professional Academic and Healthcare, 3) Develop common strategic goals with well-defined milestones, 4) Prepare scientific supporting materials, 5) Investigate key challenges within the ELSI work package.